Myomo Announces Technology Licensing Program for International Markets

Goal of Business Development Program is to Expand Access of Company’s Product Line to Additional Country Markets

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has launched a business development program to bring its proprietary MyoPro orthotic product line to a greater number of country markets outside of the United States. The company will pursue technology licensing arrangements with international partners that can manufacture and distribute the MyoPro products to rehabilitation hospitals and patients in their home markets. Myomo will provide technical expertise to quickly set up local assembly and fabrication of the custom devices; assist with clinical studies and regulatory approvals; establish an in-country Myomo Academy to train clinicians how to evaluate, fit, and train new users; and provide its MyoPro Control System through a multi-year sales agreement with the distribution partner.

Myomo CEO Paul R. Gudonis stated, “We have been approached by companies with expertise in robotics, medical technology, or rehabilitation services from a number of countries, including Japan, South Korea, China, India, and several in the Mideast. While we are directly expanding our distribution networks in the U.S. and Europe, developing licensing partnerships with firms in other international markets is designed to enable us to provide our MyoPro products to a larger patient population by leveraging the existing market positions and investments that would be made by local firms that wish to capitalize on this large market opportunity.”

Myomo is working with its Boston-based law firms, Furman Gregory Deptula, which has expertise in medical device licensing for US companies seeking to expand into additional country markets, and Sunstein Kann Murphy & Timbers LLP, which specializes in intellectual property protection and has assisted Myomo with numerous U.S. and international patent filings.

Interested parties may contact Myomo directly by sending an email to Jonathan Naft, VP and General Manager-International Operations, jon@myomo.com.

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.

Forward Looking Statements

This press release contains forward-looking statements regarding the Company’s future business expectations, including adoption of MyoPro in international markets, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors. Our actual results could differ materially from those anticipated in these forward looking statements for many reasons, including, without limitation, risks related to regulatory approval and market acceptance of our products, and the other risk factors contained in our filings made with the Securities and Exchange Commission. More information about factors that potentially could affect Myomo’s business and financial results is included in Myomo’s filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Contacts

Investor Relations:

Adam S. Holdsworth

PCG Advisory, Inc.

646-862-4607

adamh@pcgadvisory.com

Public Relations:

Sarah Karr

Matter Communications

978-518-4817

myomo@matternow.com